115956-12-2 Usage
Description
(2alpha,6alpha,8alpha,9abeta)-Octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1H-indole-3-carboxylate is a complex organic compound with a unique molecular structure. It is characterized by its octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1H-indole-3-carboxylate backbone, which contributes to its specific properties and potential applications.
Uses
Used in Pharmaceutical Industry:
(2alpha,6alpha,8alpha,9abeta)-Octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1H-indole-3-carboxylate is used as an active pharmaceutical ingredient for the prevention and treatment of postoperative nausea and vomiting. Its specific mechanism of action involves acting as a serotonin (5HT3) receptor antagonist, which helps to reduce the incidence and severity of these symptoms.
Used in Anticancer Applications:
In the field of oncology, (2alpha,6alpha,8alpha,9abeta)-Octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1H-indole-3-carboxylate is used as an anticancer agent. It modulates various oncological signaling pathways, potentially exerting inhibitory effects on tumor growth and progression. Additionally, it may demonstrate synergistic anticancer effects when combined with conventional chemotherapeutic drugs, enhancing chemo-sensitivity and efficacy in resistant cases.
Used in Drug Delivery Systems:
To improve the delivery, bioavailability, and therapeutic outcomes of (2alpha,6alpha,8alpha,9abeta)-Octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1H-indole-3-carboxylate, novel drug delivery systems have been developed. These systems employ various organic and metallic nanoparticles as carriers, aiming to enhance the compound's efficacy against cancer cells and other medical applications.
Chemical Properties:
(2alpha,6alpha,8alpha,9abeta)-Octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1H-indole-3-carboxylate is a white solid, indicating its potential for formulation into various dosage forms for pharmaceutical use.
Brand Name:
Anzemet (Sanofi Aventis) is a brand name under which (2alpha,6alpha,8alpha,9abeta)-Octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1H-indole-3-carboxylate may be marketed, specifically for the prevention of postoperative or chemotherapy-induced nausea.
Check Digit Verification of cas no
The CAS Registry Mumber 115956-12-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,5,9,5 and 6 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 115956-12:
(8*1)+(7*1)+(6*5)+(5*9)+(4*5)+(3*6)+(2*1)+(1*2)=132
132 % 10 = 2
So 115956-12-2 is a valid CAS Registry Number.
InChI:InChI=1/C19H20N2O3/c22-17-10-21-13-5-12(17)6-14(21)8-15(7-13)24-19(23)18-16-4-2-1-3-11(16)9-20-18/h1-4,12-15H,5-10H2
115956-12-2Relevant articles and documents
Dolasetron N-oxide, preparation method and application thereof
-
Paragraph 0083-0085, (2021/06/26)
The invention relates to a dolasetron N-oxide with a structure shown in a formula (I) or a salt thereof, and a preparation method and application of the compound, wherein the compound has a relatively strong inhibition effect on kinases Lyn and MST1, and can be used as an antitumor drug.
Dolasetron mesylate crystal form and preparation method
-
Paragraph 0045; 0048, (2019/04/04)
The invention provides a dolasetron mesylate crystal form. The molecular structural formula is represented in the description. The crystal form is a white powdery crystal, molecular composition is C19H20N2O3.CH3SO3H.H2O, a reflection angle 2 theta of X-ray powder diffraction of the crystal form has characteristic peaks at 11.8 degrees, 12.1 degrees, 15.1 degrees, 15.4 degrees, 22.9 degrees, 26.6 degrees, 29.9 degrees and 30.1 degrees, and differential scanning calorimetry shows that three absorption peaks exist at 150 DEG C, 164 DEG C and 260 DEG C. According to the dolasetron mesylate crystalform, product purity is high, few single impurities are contained, and heat stability of the crystal form is good. The invention further provides a preparation method of the dolasetron mesylate crystal form.
INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON
-
Page/Page column 12, (2009/05/28)
The present invention relates to intermediates useful in the synthesis of Dolasetron and synthetic precursors thereof, as well as to processes for obtaining them. In addition, it refers to the hydrochloric salt of Dolasetron and polymorphic forms of Dolasetron and precursors thereof.
